Six papers
by Marjory Moreau
published in 2020
- L Hedges, S Brown, AK MacLeod, M Moreau, M Yoon, MR Creek, TG Osimitz, and BG Lake. Metabolism of bifenthrin, β-cyfluthrin, λ-cyhalothrin, cyphenothrin and esfenvalerate by rat and human cytochrome P450 and carboxylesterase enzymes. Xenobiotica 50 (12) : 1434-1442 (Dec 22, 2020). [abstract] [pubmed]
- LG Higgins, LR Chatham, SL Tomczynski, AK MacLeod, M Moreau, HJ Clewell, M Yoon, MR Creek, TG Osimitz, and BG Lake. Differential lymphatic versus portal vein uptake of the synthetic pyrethroids deltamethrin and cis-permethrin in rats. Toxicology 443 : 152563 (Oct 14, 2020). [abstract] [pubmed]
- P Mallick, G Song, AY Efremenko, SN Pendse, MR Creek, TG Osimitz, RN Hines, P Hinderliter, HJ Clewell, BG Lake, M Yoon, and M Moreau. Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids. Toxicol Sci 176 (2) : 460-469 (Aug 1, 2020). [abstract] [pubmed]
- MW Dzierlenga, M Moreau, G Song, P Mallick, PL Ward, JL Campbell, C Housand, M Yoon, BC Allen, HJ Clewell, and MP Longnecker. Quantitative bias analysis of the association between subclinical thyroid disease and two perfluoroalkyl substances in a single study. Environ Res 182 : 109017 (Mar 9, 2020). [abstract] [pubmed]
- T Beames, M Moreau, LA Roberts, K Mansouri, S Haider, M Smeltz, CI Nicolas, D Doheny, MB Phillips, M Yoon, RA Becker, PD McMullen, ME Andersen, RA Clewell, and JK Hartman. The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay. Toxicol Appl Pharmacol 387 : 114774 (Jan 15, 2020). [abstract] [pubmed]
- P Mallick, M Moreau, G Song, AY Efremenko, SN Pendse, MR Creek, TG Osimitz, RN Hines, P Hinderliter, HJ Clewell, BG Lake, and M Yoon. Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans. Toxicol Sci 173 (1) : 86-99 (Jan 1, 2020). [abstract] [pubmed]